Myosin Therapeutics Secures Funding for Cancer and Neuroscience Trials

Myosin Therapeutics, Inc., a firm dedicated to pioneering treatments for cancer and neurological disorders, has made headlines by closing its second seed funding round, clinching over $3 million. This achievement comes on the heels of substantial backing from the National Institutes of Health (NIH), underscoring the promising nature of their work.

The focus of Myosin Therapeutics lies on its lead compound, MT-125, designed specifically to combat glioblastoma, one of the most aggressive forms of brain cancer, which unfortunately presents average survival rates of merely eight months. MT-125 operates by targeting a molecular nanomotor, thereby inhibiting both tumor growth and its invasive characteristics. The U.S. Food and Drug Administration (FDA) has already recognized MT-125 with orphan drug designation for malignant gliomas, a significant step reflecting its potential to make a meaningful impact on patient care.

Additionally, Myosin Therapeutics is advancing MT-110, a treatment aimed at addressing methamphetamine use disorder (MUD). With millions of individuals across the globe suffering from MUD and no FDA-sanctioned treatments available, the firm’s efforts in this area are critically needed. The latest funding influx, complemented by NIH support, will facilitate MT-110's move into Phase 1 clinical trials, marking a notable progression in the company's pipeline.

Dr. Courtney Miller, co-founder and CEO of Myosin Therapeutics, emphasized the importance of this funding by stating, "This funding is pivotal as it will allow us to initiate multiple clinical trials this year, including a Phase 1b trial for MT-125 in glioblastoma patients. We are deeply grateful to our investors for their support as we work to bring innovative therapies to patients with cancer and substance use disorders."

The successful seed funding round saw participation from notable investors, including DeepWork Capital, Florida Opportunity Fund, Mint12 Pharma, and Dynagrow Capital. Other contributors included Mayo Clinic Ventures and The Sontag Innovation Fund, which seeks to transform the standard of care in brain cancer treatment. Dave Adams, co-founder of Mint12 Pharma, remarked on the impressive trajectory of Myosin Therapeutics, stating, "They exemplify a well-run organization, consistently achieving key milestones to advance MT-125 and MT-110. Their commitment to innovative treatments for devastating conditions is inspiring, and we are confident in their ability to deliver meaningful solutions to patients."

Based in Jupiter, Florida, Myosin Therapeutics originated from the Herbert Wertheim UF Scripps Institute, formerly known as Scripps Research, Florida. The company has centered its research around therapies targeting molecular nanomotor proteins, demonstrating a focused commitment to addressing pressing health concerns in neuroscience and oncology.

With their latest advancements and funding success, Myosin Therapeutics is set to make significant strides in the fight against some of the most challenging medical conditions affecting patients today. Their work stands as a beacon of hope for those who grapple with cancer and substance abuse disorders, affirming the role of innovation in developing effective therapeutic options.

In conclusion, as Myosin Therapeutics prepares to launch these vital clinical trials, the medical community and potential patients alike eagerly await the results that could pave the way for groundbreaking treatments in the near future.